6 Minutes
by Michael Woodhead
August 20, 2010
Immunisation experts say there is no immediate need to consider switching from the current quadrivalent HPV vaccine (Gardasil) to a ‘stronger’ bivalent vaccine (Cervarix).
The First International HPV Vaccine Information Clearinghouse
6 Minutes
by Michael Woodhead
August 20, 2010
Immunisation experts say there is no immediate need to consider switching from the current quadrivalent HPV vaccine (Gardasil) to a ‘stronger’ bivalent vaccine (Cervarix).
Medicine Journal Feeds
AIDS. 2010 Aug 11;
Authors: Kuhn L, Wang C, Tsai WY, Wright TC, Denny L
BACKGROUND:: Cervical cancer prevention should be provided as part of primary healthcare services for HIV-infected women but conventional screening programs are difficult to implement in low-resource settings.
Medicine Journal Feeds
Gynecol Oncol. 2010 Aug 14;
Authors: Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK
OBJECTIVE: Testing for human papillomavirus (HPV) 16 and 18 genotypes, which are known to cause approximately 65-70% of invasive cervical cancer cases, may allow clinicians to identify women at highest risk for underlying cervical intraepithelial neoplasia missed by Pap cytology.
OpEdNews
By K.L. Carlson
August 18, 2010
According to FDA documents, HPV infections do not lead to cervical cancer. “Most infections by HPV are short-lived and not associated with cervical cancer,” states an FDA news release dated March 31, 2003. According to another FDA document, the Gardasil vaccine has been found to increase the risk of developing precancerous lesions by more than 44 percent in young women already infected with the HP virus strains used in the vaccine.
Roche.com
Basel, 11 April 2007
Roche to develop and commercialize products from Transgene’s programme.
Roche and Transgene announced today that they have entered into an exclusive worldwide collaboration agreement to develop and commercialize products from Transgene’s therapeutic vaccine program against Human Papilloma Virus-mediated diseases.